Canadian researchers have discovered a molecular indicator of a mechanism that drives cancer progression, giving doctors the possibility of using precision medicine, that is, choosing which patients will respond to a particular anticancer drug. In a study published in Cancer Research, a team of biochemists at Université de Montreal found that a group of enzymes…
